Interesting ABBV Put And Call Options For March 27th

AbbVie (ABBV) trading at $216.85 is the subject of two options ideas: a sell-to-open $190 put (bid $1.20) which sets an effective purchase basis of $188.80 and is ~12% OTM with an 85% analytical probability of expiring worthless, yielding 0.63% on cash committed (4.61% annualized); and a buy-stock/sell-to-open $220 covered call (bid $6.45) that would produce a 4.43% return if called at the March 27 expiration, with a 53% probability of expiring worthless and a 2.97% premium boost (21.73% annualized). Implied volatilities are 36% (put) and 30% (call) versus a 12‑month trailing volatility of 27%; Stock Options Channel will track the contract odds and histories on its site.

Analysis

Market structure: Short-dated option sellers and income-oriented retail/institutional allocators win from the current pricing: selling the $190 put (collect $1.20) implies an effective entry at $188.80 vs spot $216.85 and a quoted 85% model probability of expiring worthless; covered-call sellers at $220 capture $6.45 premium for a 4.43% near-term return. The options market shows a skew (put IV 36% > call IV 30% > realized 27%), signaling asymmetric demand for downside protection that can amplify downside moves via dealer delta-hedging if volatility re-rates. Cross-asset: a volatility spike in ABBV would likely pressure equities, widen IG credit spreads and push demand into government bonds and defensive FX (USD), while reducing appetite for cyclical commodities.

Risk assessment: Tail risks include unexpected FDA decisions, patent/biosimilar developments, or a negative clinical readout — any of which could move ABBV >15–25% in days. Time horizons: immediate (days) — option theta decay and gamma risk into Mar 27; short-term (weeks/months) — earnings, trial readouts, macro shocks; long-term (years) — patent cliffs and biosimilar erosion of Humira-like revenue. Hidden dependencies: IV skew implies concentrated put buying; large cash-secured put assignment creates funding/leverage needs and potential forced selling elsewhere. Catalysts to monitor (30–90 days): company announcements, FDA calendar, sector M&A chatter, and moves in realized vol relative to 30–90d implied vol.

Trade implications: If willing to own ABBV, allocate 1–3% portfolio to selling cash-secured ABBV Mar27 $190 puts size 1–2% per strike (max notional exposure equal to desired equity cap) and cap assignment risk at $188.80; use limit orders and max loss = position size*(spot–$190) if assigned. Alternatively, establish a buy-write: buy ABBV and sell Mar27 $220 calls to harvest 4.43% to expiry (annualized ~21.7%) but cap upside; if worried about a >10% gap down, implement a collar (buy $200 puts financed by selling $220 calls). For directional protection, buy a Mar27 $185/$170 put spread if protecting a long position — cost-efficient vs long puts.

Contrarian angles: The stated 85% expire-worthless probability is model-driven and understates event risk — a 10–15% one-day downside from clinical/regulatory news would materially change P&L and assignment probabilities. The yield from selling the $190 put (0.63% over cash commitment; 4.61% annualized) undercompensates for tail regulatory risk unless position sizes are conservative; favor small, size-managed income strategies rather than concentrated short-put exposure. Watch IV thresholds: if 30d IV >40% or price gaps below $200, reduce short-put/covered-call sizing and switch to defined-risk spreads.

Key Decisions for Investors

• Establish a tactical 1–3% portfolio position in ABBV via selling cash‑secured Mar27 $190 puts (collect $1.20) only if comfortable being assigned at $188.80; size each sale so total notional equals intended equity exposure and cap aggregate put exposure to 3% of portfolio.
• If long ABBV exposure is desired immediately, buy shares and implement a buy‑write: sell Mar27 $220 calls to capture $6.45 premium (4.43% to expiry). Use this if willing to cap upside above $220 and target ~21.7% annualized yield from rollovers.
• Use collars for material allocations (>3%): long ABBV, sell Mar27 $220 calls and buy Mar27 $200 puts to limit downside to ~7.8% from spot (cost roughly the call premium differential), adjust strikes if IV moves >+10 pts.
• If concerned about tail risk but want exposure, buy a Mar27 $185/$170 put spread as insurance (defined cost) sized at 50–75% of long position notional; exit/reevaluate if 30d IV rises above 40% or ABBV < $200.
• Avoid concentrated short‑put exposure >3% portfolio; if IV skew steepens (put IV–call IV >8 pts) or ABBV gaps >10% intraday, immediately reduce short-put size and switch to defined‑risk spreads or collars within 24–48 hours.